prikaz prve stranice dokumenta A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
  Preuzmi
PDF 681.63 KB
Znanstveni rad - Pregledni rad
A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
Diabetology, 4 (2023), 4; 440-452. https://doi.org/10.3390/diabetology4040038
Gkrinia, Elvira Meni Maria; Faour, Andrea Katrin; Belančić, Andrej; Bazile, Jacques; Marland, Emma; Vitezić, Dinko

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Gkrinia, E. M. M., Faour, A. K., Belančić, A., Bazile, J., Marland, E. i Vitezić, D. (2023). A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes. Diabetology, 4. (4), 440-452. doi: 10.3390/diabetology4040038

Gkrinia, Elvira Meni Maria, et al. "A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes." Diabetology, vol. 4, br. 4, 2023, str. 440-452. https://doi.org/10.3390/diabetology4040038

Gkrinia, Elvira Meni Maria, Andrea Katrin Faour, Andrej Belančić, Jacques Bazile, Emma Marland i Dinko Vitezić. "A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes." Diabetology 4, br. 4 (2023): 440-452. https://doi.org/10.3390/diabetology4040038

Gkrinia, E. M. M., et al. (2023) 'A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes', Diabetology, 4(4), str. 440-452. doi: 10.3390/diabetology4040038

Gkrinia EMM, Faour AK, Belančić A, Bazile J, Marland E, Vitezić D. A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes. Diabetology [Internet]. 13.10.2023. [pristupljeno 07.05.2024.];4(4):440-452. doi: 10.3390/diabetology4040038

E. M. M. Gkrinia, A. K. Faour, A. Belančić, J. Bazile, E. Marland i D. Vitezić, "A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes", Diabetology, vol. 4, br. 4, str. 440-452, Listopad 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:379724. [Citirano: 07.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:379724
Podaci o radu
Naslov (engleski)A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes
AutorElvira Meni Maria Gkrinia
AutorAndrea Katrin Faour
AutorAndrej Belančić
AutorJacques Bazile
AutorEmma Marland
AutorDinko Vitezić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Klinička farmakologija s toksikologijom
Sažetak (engleski)
Diabetes is a chronic, metabolic disease characterized by hyperglycemia, which occurs as a result of inadequate production or utilization of insulin. Type 2 diabetes (T2D) is the most common type of diabetes with estimates projecting a prevalence of more than 1 billion people living with T2DM by 2050. Hence, it was decided to conduct a systematic literature review of health economic evaluations of insulin, the most common medication used for the treatment of the disease, to inform policy. Pharmacoeconomic analyses, written in English and published after 2016, were considered for inclusion. PubMed/Medline, Global Health, Embase and Health Management Consortium were searched separately between 5 July 2023 and 17 July 2023. Grey literature articles were searched on ISPOR and the Cost-Effectiveness Analysis Registry during the same period. After the exclusion criteria were applied, 21 studies were included. Using the BMJ checklist, a quality appraisal was performed on all included studies. Data extraction was performed manually. Regarding evidence synthesis, data were heterogenous and are presented based on study type. The results showed a variety of treatment combinations being available for the treatment of diabetes, with insulin degludec/DegLira and semaglutide being cost-effective despite their high cost, due to the effectiveness of managing the disease. Research around the cost-effectiveness or cost-utility of insulin has potential to progress further, to ensure informed policy-making in the future.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetology
Brojčani podacivol. 4, br. 4, str. 440-452
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology4040038
URN:NBNurn:nbn:hr:184:379724
Datum objave publikacije2023-10-13
URL dokumentahttps://www.mdpi.com/2673-4540/4/4/38
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-10-18 10:23:26